Life Science Leader Blogs

  1. Are You Ready To Go Beyond The Cutting Edge At BIO 2016?

    Being the 2015 educational planning committee co-chair for BIO provided behind the scenes insights into what makes for a good industry session proposal at BIO. But beyond that I also learned how important it is for those interested in putting together an educational session for a conference to begin the planning process early. So when Bayer’s VP and Head of the company’s east coast innovation center, Chandra Ramanathan, Ph.D., and I sat down at last year’s annual BIO conference to discuss what type of educational session might be needed for BIO 2016, we did so armed with a wealth of wisdom.

  2. What Does The Successful Killing Of The Pfizer Allergan Deal Mean?

    When I wrote the opinion piece on the U.S. government’s successful killing of the planned Pfizer Allergan merger, it was on the heels of a March Editor’s Note on the current state of U.S. corporate taxes. There are those who argue that U.S. companies aren’t seeking to invert due to high U.S. tax rates. And while we can dispute the rationale behind why companies have been seeking to relocate outside the United States, what can’t be debated is that prior to the recent move by the U.S. Department of Treasury to block the practice, inversions were on the rise. Since 1982, 51 U.S. companies have reincorporated in low-tax countries. But more telling is that of these, 20 (inversions) happened in just the past three years, despite 2004 legislation intended to abolish the practice.

  3. Evolving The Biopharma R&D Model — Improbable Players Are Changing The Game

    At a recent conference* I overheard an executive comment that the clinical trial space remains one of the biggest bottlenecks to successful drug development. Sure, companies are developing much more sophisticated and targeted therapies. However, one of the problems this more individualized drug development creates is a slowdown in clinical trial recruitment. While new technologies are creating an enormous amount of clinical evidence, for the most part this data is being divided into two silos. On one hand we have data that is general knowledge for future cases. On the other hand, clinical care is not only creating evidence for an individual patient, but also promoting well-being. How do we bring these two silos together in an industry rapidly shifting from a pay per vial/pill model to a value-based or algorithm-driven approach? How can we actually innovate in the clinical trial space? Let’s consider a few examples of how some improbable industry outsiders have been changing the biopharmaceutical drug R&D game.

  4. Is U.S. Government Tactical Switch From Too Big To Fail To Too Big To Leave Constitutional?

    In the March 2016 issue of Life Science Leader magazine, my Editor’s Note, The U.S. Tax Man Cometh, The U.S. Corporations Leaveth, referenced the Pfizer-Allergan merger as pretty much a done deal. Little did I know then that the U.S. government would stoop to implementing government policies more familiar to those living in the former U.S.S.R., than a country founded on freedom and famous for supporting free enterprise. While not losing Pfizer (an American institution older than major league baseball) to Ireland can be considered a win for the good ‘ole US of A, I lament that the ends don’t justify the means. It seems the U.S. government has begun shifting its focus from “too big to fail,” to “too big to leave.” I for one wonder what will be the eventual outcome of such government activities in a free market society. Well for starters, Ireland-based Allergan will receive $150 million from Pfizer after the companies terminated their anticipated $150+ billion merger. A leading expert from Frost & Sullivan’s Transformational Health practice, Sangeetha Prabakaran, had this to say about the death of the recent deal.

  5. Are You Committed To Being A Better Leader?

    I recently cracked open Leadership Vertigo, a book by S. Max Brown and Tanveer Naseer. I was immediately enthralled when the authors hit me with this tidbit. “Gallup research has found that the top 25 percent of teams (i.e., the best managed) versus the bottom 25 percent in any workplace (i.e., the worst managed), have nearly 50 percent fewer accidents and 41 percent fewer quality defects.”

  6. The Best Pharma Manufacturing Conference You’ve Never Heard Of

    Thanks to Outsourced Pharma chief editor Louis Garguilo taking the lead on serving as host of Life Science Leader magazine’s annual CMO Leadership Awards celebration and reception in New York City, my time was suddenly freed up to explore for new educational opportunities. And while I will admit to being biased as to the quality of educational opportunities offered by our own Outsourced Pharma conferences, I recently got back from an event best described as one of the best pharmaceutical manufacturing educational conferences you have probably never heard of.

  7. How PhRMA Is Adapting To The Industry’s New Reality

    PhRMA held its 2016 annual meeting March 9 and 10 in Washington, D.C. This was the first annual meeting held under the new leadership regime of Stephen Ubl. Having spent more than 10 years as the president and CEO of the Advanced Medical Technology Association (AdvaMed), Ubl took the PhRMA helm just three days after former Turing Pharmaceutical CEO Martin Shkreli made national headlines with his drug-price increase antics.

  8. R&D Leadership Summit Provides Ear-Opening Experience

    Life Science Leader magazine and CNBC were the only two members of the media invited to attend the 6th Annual R&D Leadership (RDL) Summit (I will explain why this is significant in a moment). Produced by the Conference Forum with support from PRA Health Sciences, the event provides an extremely intimate opportunity for R&D executives to network and openly discuss some of the biopharmaceutical industry’s most controversial issues (e.g., drug pricing). And while you might be thinking that there are plenty of events that provide biopharmaceutical executives with a forum where they can feel free to share their most intimate feelings and opinions without fear of reprisal, what makes the RDL unique is its approach for doing so. While organizers of similar executive gatherings take “a closed-door approach” when it comes to dealing with members of the media , The Conference Forum’s executive director, Valerie Bowling, prefers a more sophisticated approach.

  9. What Will Be The End Result Of Bullying Biopharma?

    If as adults we could invisibly walk on school playgrounds during recess, we might hear the stock response recited when encountering a bully — ‘Sticks and stones may break my bones, but words will never hurt me.”

  10. BIO CEO 2016 Educational Sessions Provide Enlightenment

    During this year’s BIO CEO Conference (partially covered here), much of my time was spent in the educational sessions, which I would rank as some of the best I have seen at any conference — ever. For example ...